Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

CoreLogic Q4 Net Loss Narrows; Reconfirms FY12 Guidance - Quick Facts

RELATED NEWS
Trade CLGX now with 

CoreLogic, Inc. (CLGX: Quote) reported that its fourth-quarter net loss attributable to the company narrowed to $14.14 million or $0.13 per share, from $27.74 million or $0.24 per share in the same quarter last year.

Operating revenue for the quarter rose to $345.40 million from $315.37 million in the prior year quarter. Analysts polled by Thomson Reuters expected the company to report revenues of $330.68 million for the quarter. Analysts' estimates typically exclude special items.

The company reconfirmed its guidance for 2012. The company still expects adjusted earnings in a range of $0.95 to $1.05 and adjusted revenue of $1.425 billion to $1.475 billion for fiscal year 2012. Analysts expect the company to report earnings of $0.95 per share on revenues of $1.47 billion for fiscal 2012.

Click here to receive FREE breaking news email alerts for CoreLogic Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks came under pressure in early trading on Friday and remained firmly in the red throughout the remainder of the trading session. With the losses on the day, the S&P 500 pulled back well off yesterday's record closing high. President Barack Obama is meeting with presidents from Central American nations on Friday as the U.S. struggles to deal with a surge of unaccompanied children across the southern border. Despite calls from some leading conservatives, the results of a new CNN/ORC International poll released Friday showed that a vast majority of Americans do not believe that President Barack Obama should be impeached and removed from office.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.